Your browser doesn't support javascript.
loading
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao, Jiang; Wang, Gang; Cheng, Hai; Wei, Chen; Qi, Kunming; Sang, Wei; Zhenyu, Li; Shi, Ming; Li, Huizhong; Qiao, Jianlin; Pan, Bin; Zhao, Jing; Wu, Qingyun; Zeng, Lingyu; Niu, Mingshan; Jing, Guangjun; Zheng, Junnian; Xu, Kailin.
Afiliación
  • Cao J; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Wang G; Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
  • Cheng H; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Wei C; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Qi K; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Sang W; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Zhenyu L; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Shi M; Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
  • Li H; Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
  • Qiao J; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
  • Pan B; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
  • Zhao J; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
  • Wu Q; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
  • Zeng L; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
  • Niu M; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
  • Jing G; iCARTAB biomedical co. LTD, Suzhou, 215000, China.
  • Zheng J; Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
  • Xu K; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
Am J Hematol ; 93(7): 851-858, 2018 07.
Article en En | MEDLINE | ID: mdl-29633386
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Terapia Recuperativa / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores Quiméricos de Antígenos Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2018 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Terapia Recuperativa / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores Quiméricos de Antígenos Límite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2018 Tipo del documento: Article País de afiliación: China